Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Clinical Endocrinology
|
August 28, 2022
Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus
Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 10, 2022
Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus
Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, et al.
International Journal of Mental Health Systems
|
August 19, 2025
Suicide among youth and young adults in Canada: bereaved parents' perspectives on the systems of care
Toula Kourgiantakis, Deborah Cooper, David Cooper, et al.
Annals of Neurology
|
June 4, 2014
Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease
Martin Göttle, Cecilia N Prudente, Rong Fu, et al.
European Journal of Endocrinology
|
October 14, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Journal of Natural Products
|
January 24, 2004
Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES
Linda C Meade-Tollin, E M Kithsiri Wijeratne, Deborah Cooper, et al.
Pituitary
|
November 5, 2022
Changing the name of diabetes insipidus
Hiroshi Arima, Daniel G Bichet, Timothy Cheetham, et al.
Endocrine Connections
|
October 13, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Endocrine Journal
|
October 16, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Trials
|
July 8, 2022
Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care
Sarah L Alderson, Alexandra Wright-Hughes, Alexander C Ford, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Clinical Endocrinology
|
August 28, 2022
Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus
Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 10, 2022
Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus
Hiroshi Arima, Timothy Cheetham, Mirjam Christ-Crain, et al.
International Journal of Mental Health Systems
|
August 19, 2025
Suicide among youth and young adults in Canada: bereaved parents' perspectives on the systems of care
Toula Kourgiantakis, Deborah Cooper, David Cooper, et al.
Annals of Neurology
|
June 4, 2014
Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease
Martin Göttle, Cecilia N Prudente, Rong Fu, et al.
European Journal of Endocrinology
|
October 14, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Journal of Natural Products
|
January 24, 2004
Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES
Linda C Meade-Tollin, E M Kithsiri Wijeratne, Deborah Cooper, et al.
Pituitary
|
November 5, 2022
Changing the name of diabetes insipidus
Hiroshi Arima, Daniel G Bichet, Timothy Cheetham, et al.
Endocrine Connections
|
October 13, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Endocrine Journal
|
October 16, 2022
Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus
, Hiroshi Arima, Timothy Cheetham, et al.
Trials
|
July 8, 2022
Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care
Sarah L Alderson, Alexandra Wright-Hughes, Alexander C Ford, et al.
Page
of 4